Quick Take
- Datavault faces Nasdaq’s Aug. 24 deadline while DVLT remains 68% below the exchange’s $1 minimum bid price.
- Nasdaq may grant another 180-day cure period, but only if Datavault meets other listing standards and commits to a potential reverse split.
- No extension or delisting notice was disclosed at the latest refresh, leaving a formal exchange or company notice as the next decisive signal.
Datavault AI reaches its Nasdaq minimum bid-price deadline on Aug. 24, with DVLT 68% below the exchange's $1 threshold and no disclosed decision on whether the company will receive more time or a delisting notice.
DVLT's last sale was $0.3186 on Aug. 21, according to Nasdaq's official quote feed. Nasdaq historical data showed every close/last reading from Aug. 7 through Aug. 21 below $1.
Datavault disclosed in a Feb. 27 filing that Nasdaq had given it until Aug. 24 to regain compliance, which requires a closing bid price of at least $1 for at least 10 consecutive business days.
With only Aug. 24 left in the window, the sub-$1 close/last reading on Aug. 21 left no practical route to complete a new 10-day closing-bid cure.
Nasdaq now decides whether Datavault gets more time
Under Nasdaq's compliance rules, a Capital Market issuer can receive another 180 days if it meets the applicable continued-listing test for market value of publicly held shares and every other initial listing standard except bid price.
The company must also give Nasdaq written notice that it intends to cure the deficiency during the second period through a reverse stock split if necessary, which serves as a commitment to a potential cure.
Datavault's June-quarter filing reported $245.9 million of stockholders' equity and 949.7 million shares outstanding as of Aug. 19. At $0.3186, that share count implies about $302.6 million of total equity market value.
Total market value is not Nasdaq's unrestricted public-float measure, and public filings do not establish required holder and market-maker counts. Nasdaq still controls the eligibility determination.
The timestamped SEC submissions feed and Datavault's press-release index showed no extension or Staff Delisting Determination at the Aug. 24 refresh.
The only authority located in the reviewed SEC filings was a 2025 authorization permitting a 1-for-5 to 1-for-20 split no later than that year's annual meeting. The SEC submissions feed showed no newer proxy or information statement granting replacement authority.
A reverse split would mechanically reduce the share count and, absent other factors, raise the per-share price. It would not itself create economic value, guarantee that DVLT stays above $1, or resolve Datavault's separate capital needs.
Datavault agreed to sell 109.1 million shares at $0.55 in May and reported $1.4 million of cash alongside $79.96 million of operating cash use for the first half. Recent reports detailed those financing pressures in connection with the company's proposed bank acquisition.
The decisive signal is now a formal exchange or company notice. An additional period would postpone the bid-price test, while a Staff Delisting Determination would begin the next listing process.
Facts Only
Datavault AI (DVLT) faces a Nasdaq minimum bid-price deadline on August 24.
The Nasdaq minimum bid price is $1.
DVLT's last sale price was $0.3186 on August 21.
Every close or last reading from August 7 through August 21 was below $1.
Regaining compliance requires a closing bid price of at least $1 for 10 consecutive business days.
Datavault reported $245.9 million of stockholders' equity and 949.7 million shares outstanding as of August 19.
Datavault possesses a 2025 authorization for a 1-for-5 to 1-for-20 reverse stock split.
Datavault sold 109.1 million shares at $0.55 in May.
The company reported $1.4 million of cash and $79.96 million of operating cash use for the first half of the year.
No extension or Staff Delisting Determination was disclosed as of the August 24 refresh.
Executive Summary
Datavault AI is currently at risk of delisting from the Nasdaq as it reaches its August 24 compliance deadline. The company's share price has remained significantly below the required $1 minimum, most recently closing at $0.3186. Because compliance requires ten consecutive business days above the threshold, there is no longer a practical path to meet this requirement before the deadline.
The company may avoid immediate delisting if Nasdaq grants a 180-day cure period. This extension is contingent upon Datavault meeting other listing standards regarding market value and providing a written commitment to perform a reverse stock split if necessary. While the company has authorization for such a split, it has not yet triggered the process.
Financial pressures complicate the situation, as the company reports minimal cash reserves relative to high operating cash use and ongoing financing needs related to a proposed bank acquisition. The final outcome depends on a forthcoming formal notice from the exchange or the company.
Full Take
The strongest version of this narrative is a straightforward account of regulatory compliance and the mechanical risks of penny-stock volatility. It highlights the tension between a company's operational ambitions—such as a bank acquisition—and the rigid requirements of a major exchange.
The narrative follows a standard financial reporting pattern: focusing on the "bid-price" trigger while treating the reverse split as a mechanical solution. However, the root cause of the instability is not the bid price itself, but a severe liquidity gap, evidenced by $1.4 million in cash against nearly $80 million in operating outflows. The assumption is that maintaining a listing is the primary goal, yet the underlying economic value remains unchanged regardless of the share count.
This situation echoes a common pattern in small-cap equities where reverse splits are used as a regulatory shield to buy time, rather than a signal of fundamental growth. The benefit of an extension accrues to the company's leadership and existing shareholders who wish to avoid the liquidity drop of the OTC markets; the cost is borne by new investors who may mistake a mechanical price increase for a recovery in value.
Patterns detected: none
Bridge Questions:
1. If a reverse split is implemented, does it address the operational cash burn or merely the regulatory symptom?
2. How does the proposed bank acquisition align with the current equity market value and cash position?
3. What would happen to the company's financing ability if it were forced to move to an over-the-counter exchange?
Counterstrike Scan: An influence campaign would likely use "fear of missing out" (FOMO) by framing the reverse split as a "catalyst" for a price surge to trap retail investors. The actual content here is a neutral presentation of regulatory deadlines and financial deficits, showing no alignment with such a pattern.